Antibody method for treatment of a disease in which the target cells are cells which express CD20

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9873745
SERIAL NO

14828177

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
LFB BIOTECHNOLOGIESFRANCE LEVIN FORURIS LES ULIS ESSONNE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
De, Romeuf Christophe Lambersart, FR 42 230
Gaucher, Christine Sequedin, FR 17 75
Prost, Jean-Francois Versailles, FR 3 15
Teillaud, Jean-Luc Paris, FR 7 71

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jul 23, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 23, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00